The company said emricasan, its drug to treat nonalcoholic steatohepatitis, a fatty liver disease, failed to beat a placebo in its midstage clinical trial. It is discontinuing the trial altogether.
In March, the drug failed in a clinical trial with patients with biopsy-confirmed nonalcoholic steatohepatitis and liver fibrosis, and last year it failed to stop or reverse damage to liver transplants caused by hepatitis C.
The company said it is now exploring “strategic alternatives to enhance shareholder value,” including a sale.
The company will also halt development of one of its lead drug candidates for inflammasome disease, CTS-2090.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
